Big Pharma’s Astronomical Profits from the Covid Vaccination New World Order Religion By Brian Simpson
The Big Pharma vax companies are proclaiming a return to normal, but only if everyone is vaccinated, with unending booster shots, at least annually, but Covid guru Dr Fauci wants them every five months. Trump thought that there would be just one vaccine, and that is it. He should have got better informed. But he is right in his more recent revelation that this will generate massive profits for Big Pharma. How much profit? “Most vaccines given so far in the U.S. have come from Pfizer and BioNTech. Morningstar analyst Karen Andersen expects boosters alone to bring in about $26 billion in global sales next year for Pfizer — who splits profits with BioNTech — and around $14 billion for Moderna if they are endorsed for nearly all Americans. Pfizer executives said they expect their pre-tax adjusted profit margin from the vaccine to be in the “high 20s” as a percentage of revenue. That would translate to an estimated profit of $7 billion next year just from boosters, according to Anderon’s sales prediction. This year alone, Pfizer expects its COVID vaccine to generate $33.5 billion in revenue with vaccine supply agreements worth more than $60 billion in sales, just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.”
I think I could put together a film script about this, adding some imaginative and literary leaps, a type of James Bond adventure. But reality would trump fiction.
“On Sept. 26, Pfizer CEO and Chairman Albert Bourla predicted life will return to normal within a year, but it’s likely annual COVID vaccinations will be necessary.
Bourla’s vision for a “return to normal life” would position Pfizer and Moderna to make billions in profits dispensing endless booster doses. How much the manufacturers stand to gain depends on how big the rollout is.
“Within a year I think we will be able to come back to normal life,” Bourla said in an interview on ABC’s “This Week.”
Bourla said he does not think this means variants will no longer exist, or that we “should be able to live our lives without having vaccinations.”
The “most likely scenario,” Bourla said, is annual vaccination with vaccines that last at least a year, “but we don’t know really, we need to wait and see the data.”
Bourla’s prediction echoed that of Moderna CEO Stéphane Bancel, who when asked last week for his estimate of a return to normal life, told Swiss newspaper Neue Zuercher Zeitung the COVID pandemic could be over in a year.
Moderna on Sept. 1 asked the U.S. Food and Drug Administration (FDA) to authorize the use of a third booster dose of its COVID vaccine.
Johnson & Johnson still has to submit the data for its booster shot to the FDA for approval, although the company has said it does not plan to profit from its vaccine during the pandemic.
According to the Associated Press (AP), the average forecast among analysts for Moderna’s 2022 revenue jumped 35% after President Biden laid out his booster plan in mid-August.
Most vaccines given so far in the U.S. have come from Pfizer and BioNTech. Morningstar analyst Karen Andersen expects boosters alone to bring in about $26 billion in global sales next year for Pfizer — who splits profits with BioNTech — and around $14 billion for Moderna if they are endorsed for nearly all Americans.
Pfizer executives said they expect their pre-tax adjusted profit margin from the vaccine to be in the “high 20s” as a percentage of revenue. That would translate to an estimated profit of $7 billion next year just from boosters, according to Anderon’s sales prediction.
This year alone, Pfizer expects its COVID vaccine to generate $33.5 billion in revenue with vaccine supply agreements worth more than $60 billion in sales, just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.
Pfizer’s COVID vaccine is projected to make up 42% of the company’s total revenue, and will bring more than five times the $5.8 billion racked up last year by the world’s most lucrative vaccine — Pfizer’s Prevnar13 — a vaccine for pneumococcal disease.
This bodes well for future vaccine development, said Erik Gordon, a business professor at the University of Michigan. Vaccines normally are nowhere near as profitable as treatments, Gordon said. But the success of the COVID shots could draw more drugmakers and venture capitalists into the field.
For Pfizer and Moderna, boosters could be more profitable than original doses because they won’t come with the research and development costs the companies incurred to get the vaccines initially on the market, AP reported.
WBB Securities CEO Steve Brozak said the booster shots will represent “almost pure profit” compared with the initial doses.
There is opportunity for Pfizer to generate similar — or higher — levels of revenue in the future as experts predict COVID is here to stay.
The FDA last week authorized a third dose of Pfizer’s vaccine for some individuals — those 65 and older and also those “whose frequent institutional or occupational exposure” to the virus puts them at high risk of serious complications from the disease caused by the virus, the agency said.
On Sept. 17, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), a group of scientists who advise the FDA on vaccine approvals, unanimously recommended Emergency Use Authorization for a booster dose of Pfizer’s vaccine for people 65 and older and those with compromised immune systems — but voted 16 – 2 against recommending boosters for the general population, citing a lack of long-term data. The committee said the risks did not outweigh the benefits for those people.
The decision was perceived as a major rebuke of the Biden administration, STAT reported. And it closely followed the resignations of Marion Gruber and Phil Krause, two key FDA vaccine regulators who announced their resignations days after Biden’s initial booster announcement.
On Sept. 24, Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), ignored the advice of the agency’s vaccine advisory committee, clearing the way for healthcare workers, teachers, grocery store workers, residents of long-term care facilities, homeless shelters, prisons and anyone else considered “high risk” to receive a third Pfizer shot.”
“The advent of coronavirus booster shots could rake in billions of dollars in profits for companies like Pfizer and Moderna, according to the Associated Press (AP).
“Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans’ protection against the virus,” reported the AP. “How much the manufacturers stand to gain depends on how big the rollout proves to be.”
Though the U.S. Food and Drug Administration (FDA) has only approved the Pfizer booster shot for Americans 65 and older as well as high-risk Americans, experts predict booster shots will soon be available for all Americans, which will include products from Moderna and Johnson & Johnson. With that comes big profits, especially when factoring in that companies will not have the same massive overhead costs of research and development as the initial shots. Currently, the average forecast among Wall Street analysts for “Moderna’s 2022 revenue has jumped 35% since President Joe Biden laid out his booster plan in mid-August,” according to the AP.
“The opportunity quite frankly is reflective of the billions of people around the world who would need a vaccination and a boost,” Jefferies analyst Michael Yee told the outlet.
Since the vaccines were widely distributed in the United States, Pfizer has inoculated roughly 99 million people while Moderna has vaccinated 68 million; Johnson & Johnson has only vaccinated 14 million people. Regarding booster shots, Morningstar analyst Karen Andersen told the Associated Press that Pfizer and BioNTech could bring in $26 billion in 2022, while Moderna could profit $13 billion next year “from all COVID-19 vaccine sales if boosters are broadly authorized.”
“Potential vaccine profits are harder to estimate for Pfizer, but company executives have said they expect their pre-tax adjusted profit margin from the vaccine to be in the ‘high 20s’ as a percentage of revenue,” noted the AP. “That would translate to a profit of around $7 billion next year just from boosters, based on Andersen’s sales prediction.”
“J&J and Europe’s AstraZeneca have said they don’t intend to profit from their COVID-19 vaccines during the pandemic,” the report added.
During an appearance on ABC’s This Week on Sunday, Pfizer CEO Dr. Albert Bourla predicted that “the most likely scenario is annual revaccination” against the coronavirus.
“The most likely scenario for me, it is because the virus has spread all over the world, that we will continue seeing new variants that are coming out, and also we will have vaccines that will last at least a year. I think the most likely scenario is annual revaccinations, but we need to wait and see the data,” he said.”
Comments